Sustiva
Formulated to address human immunodeficiency virus infection, developed to mitigate viral replication and support immune health within established treatment regimens.
- Category
- HIV Management
- Active ingredient
- Efavirenz
- Supply
- Rx
- Route
- Oral use
- Form
- Film-coated tablet
- Strengths
- 200 · 600mg
Sustiva details
- Condition
- HIV Infection
- Therapeutic class
- Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)
- Pharmacological class
- NNRTI
- Minor side effects
- dizziness; headache; nausea; rash
- Moderate side effects
- insomnia; vivid dreams; elevated liver enzymes
- Dosage forms
- Film-coated tablet
- Administration route
- Oral use
- Supply category
- Prescription only (specially controlled medicine)
- Manufacturer
- Bristol-Myers Squibb
- Onset Time
- 1–2 weeks
- Duration
- 24 hours
- Storage instructions
- Store at room temperature away from moisture.
- Drug interactions
- St. John's Wort; midazolam; ethinylestradiol
- Age restrictions
- Paediatric use depends on weight and product formulation.
Contraindications
hypersensitivity to efavirenz; severe hepatic impairment; concurrent use of elbasvir/grazoprevir; concurrent use of voriconazole
Precautions and warnings
may cause dizziness and confusion; monitor for rash; monitor liver enzymes; avoid driving if dizziness occurs
Serious side effects
severe skin reactions, requires immediate medical attention; psychosis, requires immediate medical attention; convulsions, requires immediate medical attention
Patient summary
Formulated to address human immunodeficiency virus infection, developed to mitigate viral replication and support immune health within established treatment regimens.
Mechanism of action
Efavirenz is a non-nucleoside reverse transcriptase inhibitor. It binds directly to the HIV-1 reverse transcriptase enzyme, causing a conformational change that inhibits its activity and prevents the conversion of viral RNA into DNA, thus blocking viral proliferation.
Pregnancy and breastfeeding
Avoid during the first trimester of pregnancy due to risk of neural tube defects. Discuss alternatives with a specialist.
Where this medicine is registered
- Singapore
- Hong Kong
- Thailand
- Malaysia
- Philippines
- Indonesia
- Taiwan
- South Korea
- Japan
- Australia
- New Zealand
- UAE
- South Africa
About Sustiva
Sustiva is an antiviral medication containing efavirenz, used for the management of HIV infection. Developed by Bristol-Myers Squibb, this treatment is manufactured as a tablet in 200mg and 600mg strengths. It is designed to assist in controlling viral replication to support immune health.
Sustiva availability in Asia
Sustiva is registered across 14 markets, including South Korea, Japan and the UAE, with availability also in Singapore, Hong Kong and Thailand. Generic versions of efavirenz, often manufactured in India, are significantly more affordable than the original brand, providing reliable access for expats and individuals residing far from a consistent local supply. This medication is best used under the ongoing care of a doctor.